Public Workshop: Safe Use of Benzodiazepines: Clinical, Regulatory, and Public Health Perspectives

Public Workshop: Safe Use of Benzodiazepines: Clinical, Regulatory, and Public Health Perspectives

Duke University’s Margolis Center for Health Policy, in cooperation with the FDA, held a public workshop Safe Use of Benzodiazepines: Clinical, Regulatory, and Public Health Perspectives on July 12 and 13. Our director, Dr. Christy Huff,…

BIC Supports FDA’s Benzodiazepine Drug Abuse, Addiction and Dependence Language Proposal

BIC Supports FDA’s Benzodiazepine Drug Abuse, Addiction and Dependence Language Proposal

Benzodiazepine Information Coalition recently responded to the FDA’s Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products. This document proposed by the FDA seeks to distinguish the difference between addiction,…

The FDA Adds an (Incomplete) Black Box Warning on Benzodiazepines

The FDA Adds an (Incomplete) Black Box Warning on Benzodiazepines

On August 31, 2016 the FDA issued a statement about benzodiazepines receiving a black box warning in relation to combining with opiates.  This warning is late and incomplete.  The dangers of opiates and benzodiazepines needed to be addressed,…